what is the difference between dpp-4 inhibitors and glp-1 analogs GLP-1-based therapies: current knowledge of differences native Neuroprotection by dipeptidyl-peptidase-4 inhibitors and

In patients with diminished beta cell function the glycemic response to GLP-1 RAs therapy is reduced (286)

Geng, J., Dong, J., Ni, H., Lee, M

FDA staff and opposing groups argue that adding these compounds to the legal compounding list without adequate human safety data would legitimize unvetted foreign supply chains and create a false assurance of safety through the appearance of regulatory sanction

By activating these receptors in the brains satiety centers (like the area postrema), it promotes feelings of fullness, reduces food intake, and helps stabilize post-meal blood sugar spikes, making it a promising candidate for weight management, particularly in combination with the GLP-1 receptor agonist semaglutide (marketed as CagriSema)